These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

811 related items for PubMed ID: 8646674

  • 1. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H.
    Cancer; 1996 May 01; 77(9):1781-6. PubMed ID: 8646674
    [Abstract] [Full Text] [Related]

  • 2. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N.
    Ann Surg Oncol; 2009 Oct 01; 16(10):2795-804. PubMed ID: 19669841
    [Abstract] [Full Text] [Related]

  • 3. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA, Blatt LM, Corey WG, Lin JH, Han S, Saab S, Busuttil RW, Tong MJ.
    J Gastroenterol Hepatol; 2008 Oct 01; 23(10):1541-8. PubMed ID: 18422961
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A, Taniguchi K, Inoue S, Harada A, Nonami T, Watanabe K, Takagi H.
    Semin Surg Oncol; 1996 Oct 01; 12(3):160-3. PubMed ID: 8727604
    [Abstract] [Full Text] [Related]

  • 5. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y.
    Hepatogastroenterology; 1998 Oct 01; 45(23):1737-41. PubMed ID: 9840138
    [Abstract] [Full Text] [Related]

  • 6. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K, Takase K, Tameda Y, Nakano T.
    Int J Mol Med; 2002 Mar 01; 9(3):245-50. PubMed ID: 11836630
    [Abstract] [Full Text] [Related]

  • 7. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M, Nakano M.
    Cancer; 2000 Feb 01; 88(3):544-9. PubMed ID: 10649245
    [Abstract] [Full Text] [Related]

  • 8. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, Magario N, Yokoo T, Naraki T.
    Cancer; 1999 Feb 15; 85(4):812-8. PubMed ID: 10091758
    [Abstract] [Full Text] [Related]

  • 9. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K, Shigematsu H, Irie K, Ishibashi H.
    Hepatogastroenterology; 2003 Feb 15; 50(54):2072-8. PubMed ID: 14696467
    [Abstract] [Full Text] [Related]

  • 10. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
    Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T.
    Hepatogastroenterology; 1995 Feb 15; 42(4):387-93. PubMed ID: 8586374
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y.
    Am J Gastroenterol; 2006 Sep 15; 101(9):2038-43. PubMed ID: 16848811
    [Abstract] [Full Text] [Related]

  • 12. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study.
    Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y.
    Hepatogastroenterology; 2002 Sep 15; 49(43):235-8. PubMed ID: 11941963
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.
    Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, Oka H, Yamazaki O, Manabe T, Urano F, Chung H, Kudo M, Matsunaga T.
    J Hepatol; 2008 Aug 15; 49(2):223-32. PubMed ID: 18571271
    [Abstract] [Full Text] [Related]

  • 14. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers.
    Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, Kawabe T, Omata M.
    Hepatology; 2006 Dec 15; 44(6):1518-27. PubMed ID: 17133456
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
    Inoue S, Nakao A, Harada A, Nonami T, Takagi H.
    Am J Gastroenterol; 1994 Dec 15; 89(12):2222-6. PubMed ID: 7526679
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan 15; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 18. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S, Morishita T, Shibata J, Sato T.
    Gan To Kagaku Ryoho; 1989 Apr 15; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [Abstract] [Full Text] [Related]

  • 19. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R, Runge M, Stieber P, Meissner E.
    Anticancer Res; 1999 Apr 15; 19(4A):2489-93. PubMed ID: 10470180
    [Abstract] [Full Text] [Related]

  • 20. Coagulation assays as diagnostic markers of hepatocellular carcinoma.
    Lefrère JJ, Conard J, Mavier P, Bettan L, Beaugrand M, Gozin D, Lerable J, Dhumeaux D, Samama M.
    Thromb Haemost; 1988 Dec 22; 60(3):468-70. PubMed ID: 2467402
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.